The embattled blood testing firm's move comes after regulators found Theranos failed to implement proper patient safeguards in its study. Fred Katayama reports.
Another blow for Theranos and its founder, Elizabeth Holmes. The Wall Street Journal reports the blood testing firm has withdrawn its request for emergency clearance of a blood test for the mosquito-borne Zika virus. It said the Food and Drug Administration found that Theranos had collected data to support the test's accuracy without implementing proper patient safeguards. The company wasn't immediately available for comment. The Journal said Theranos plans to collect more data and resubmit its application. This development comes just weeks after Holmes unveiled a product that she said can run tests for the Zika virus, detecting additional strains from blood drops collected by pricking the fingers of patients. She said such new technologies were separate from the operations of its clinical labs that have come under scrutiny. Regulators have barred her from running a lab and revoked Theranos' certificate for its California lab, saying its practices were jeopardizing patient health and safety.